Helix BioPharma (TSE:HBP) Share Price Crosses Below 50-Day Moving Average – Here’s Why

Helix BioPharma Corp. (TSE:HBP) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$1.49 and traded as low as C$1.41. Helix BioPharma shares last traded at C$1.44, with a volume of 1,100 shares.

Helix BioPharma Trading Down 1.4%

The firm has a market capitalization of C$108.46 million, a PE ratio of -35.50 and a beta of 0.43. The company has a quick ratio of 1.03, a current ratio of 0.45 and a debt-to-equity ratio of 2.44. The stock’s fifty day simple moving average is C$1.49 and its 200 day simple moving average is C$1.78.

Helix BioPharma (TSE:HBP) last released its quarterly earnings results on Friday, June 12th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. On average, sell-side analysts predict that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.